Click HERE to register for a LIVE presentation from industry expert Jose Galarza on The Role of the Virus-Like Particle (VLP) Vaccine Technology in the Evolving SARS-COV-2 Pandemic and It’s Unique Advantages in an Overcrowded Vaccine Field.
The emergence of SARS-CoV-2 and the ensuing COVID-19 pandemic has refocused attention on the value of vaccines in society as well as on the technologies utilized to develop and produce these life-saving products. Multiple approaches, some of which are new to the field, are being used for the development of SARS-CoV-2 vaccines. The rapid evolution of the virus and the emergence of new antigenic variants, however, present new challenges to the field, which must rethink the creation not only of new vaccines with broader antigenic coverage,but also of formulations that afford enhanced duration of the elicited immunity. In consideration of this evolving environment, I will discuss the coronavirus-like particle (VLP) technology and its applications which are designed to tackle the challenges resulting from persistent SARS-CoV-2 circulation, which drives antigenic evolution of variants and may reduce the efficacy of currently available vaccines. TheVLP approach represents the next generation of COVID-19 vaccines and will offer a novel and efficacious strategy for addressing the pressing issue of antigenic diversity as well as the magnitude, quality and duration of immunity. In addition, I will present data on VLP vaccine production in which I will cover both upstream and downstream processes as well as the characterization and testing of the vaccine product. Furthermore, I will describe results from preclinical studies in small animal models and the resulting immunogenicity data. Lastly, I will perform a comparative analysis of this VLP technology and the platforms of the currently available vaccines, highlighting the advantages of the former with respect to addressing the challenges of this evolving pandemic.
Click HERE to register.